Latanoprost Actavis (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary muscle, triggering remodeling of extracellular matrix proteins. This process enhances uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure, which is the primary therapeutic target in glaucoma management.

The dosing regimen is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing are individualized based on patient response and clinical judgment.

The pregnancy category for latanoprost is unknown. It should only be used during pregnancy or lactation if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker eye drops such as timolol, latanoprost often provides greater pressure‑lowering efficacy and a more convenient dosing schedule, though individual response varies.

Store the ophthalmic solution at room temperature below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain sterility.

Latanoprost is applied as a single drop to the conjunctival sac of the affected eye(s) in the evening. The patient should wash hands, avoid touching the tip of the bottle to the eye or any surface, and gently close the eye for a few minutes after instillation.

Serious adverse events, although rare, include uveitis, corneal edema, and severe allergic reactions such as swelling or difficulty breathing. Patients should seek immediate medical attention if they experience any of these symptoms.

Latanoprost is contraindicated in patients with active ocular inflammation, such as uveitis or ocular infection, and in individuals with known hypersensitivity to latanoprost or any component of the formulation. Caution is also advised for patients with severe corneal disease.